Forian Inc.

Greetings and welcome to Forian's Inc. Second Quarter 2025 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal comments and webcast. Participating today from Forian are Max Weigod, Executive Chairman and Chief Executive Officer, and Michael Vesey, Chief Financial Officer. Before we begin, I would like to remind you that management's remarks today may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by those forward-looking statements due to a variety of important factors, including those discussed in the risk factor sections of the company's annual report on Form 10-K filed with the SEC on April 11, 2025. In particular, management will discuss an estimate of its full-year 2025 revenue outlook as of today. Estimating financial performance accurately for future performance is difficult as it involves assumptions and internal estimates. that may prove to be incorrect and is based on plans and circumstances that may change. There is therefore a significant risk that actual results could differ materially from the outlook provided today. Any forward-looking statements made on the call today represents the company's view as of this date. and the company undertakes no obligation to update them except as required by law. Words such as estimate, projected, expect, anticipate, forecast, planned, intend, believe, seek, may, will, should, future, propose, and variations of these words or similar expressions or versions of such words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding future growth, anticipated performance, and prospects. Today's presenters will also refer to certain non-GAAP financial measures on our call, such as adjusted EBITDA, which the company believes may be important to investors to assess its operating performance and should be considered a supplement to and not a substitute for financial measures, prepared in accordance with GAAP. A reconciliation of the comparable gap metric can be found on today's press release and webcast, both of which are available on the company's website. Those numbers are unaudited and any statements regarding the company's anticipated performance may be subject to change, including as a result of risk, discussed in the Risk Factors section of the company's annual report on Form 10-K, filed with the SEC on April 11, 2025. Today's call and webcasts are being recorded. A copy of the recording webcast as well as the full transcript and copies of today's press release and SEC filings will be available at forian.com forward slash investors. I am now pleased to introduce the company's executive chairman and chief executive officer, Max Weigod. Sir, you may begin.

Good afternoon, everyone. Thank you for joining Forian's second quarter earnings call. I will provide an overview of Forensic's strong second quarter performance, highlighting year-over-year growth, margin improvement, and a strategic process driven by the Kyber data science acquisition. I will also discuss the company's expanding data capabilities, product innovation, and an update in meeting full-year 2025 guidance. Forin's second quarter reflected continued strength across the organization as we achieved results that were consistent with our full-year outlook. Relative to internal expectations, we are pleased with the state of our financial performance as we head into the second half of the year. Forin delivers complex healthcare information products and services by integrating one of the industry's largest longitudinal patient-level datasets, sourced from a growing network of claims, electronic health records, lab results, and other real-world data streams. We use proprietary data ingestion pipelines to unify disparate multi-format datasets into the Kronos data lake, which tracks patient journeys for hundreds of millions of de-identified individuals. In the second quarter, we continue to see growth in delivering information products with highlights in areas such as health economics and outcomes research for life-saving therapies and the Kyber Data Science Platform, which delivers alpha-generating insights for financial services clients. We have a high degree of visibility into second-half performance based off of the mix of contracted backlog and renewals in our pipeline. which gives us confidence in our full-year growth expectations. Generally, across our customer groups, our conversations continue to reflect a mixed spending environment in our healthcare and financial services and markets. While pharma companies remain cautious, driven by a rapidly changing geopolitical and macroeconomic environment, the need for analytic-ready, real-world data and longitudinal information remains to help measure effectiveness, safety, and value, as well as to better understand their respective competitive markets. Similar to the first quarter, 4N's revenue growth was highlighted by key new pharma projects and analytical renewals, as well as incorporating the full quarter of Cyber Data Sciences financials. 4N generated second quarter revenue of $7.5 million, represented 56% year-over-year growth. Our net income for the quarter was $224,000, and our adjusted EBITDA was $591,000, which compares to a loss of $2.5 million and positive $78,000 year-over-year, respectively. The improvement in expenses and margin profile were primarily driven by the realization of cost optimizations and the impact of the Kyber acquisition. These improvements in expenses show the leverage in our financial model. However, we intend to continue to enter into more strategic long-term data contracts and to make investments in enhancing our product portfolio and extending sales into new healthcare-related verticals that may impact temporarily our margin profile. In the second quarter, we expanded our data coverage by securing new supply contracts and accelerating integrations with diverse clinical data sources, an initiative fast-tracked by the market disruptions of 2024. These long-term integrations, combined with our advanced proprietary data models, position us to deliver analytics-ready solutions that meet the evolving need of our clients. We believe we are able to contract, ingest, and produce differentiated information products quicker, more accurately, and cost-effectively than our competition. When ingesting new healthcare data feeds, we are expert in the normalization and cleansing that is essential to ensure the data is consistent, accurate, and usable across multiple models. As a reminder, normalization involves standardizing code sets, formats, and identifiers so that diagnoses, procedures, drugs, and facilities are mapped to common reference standards like the ICD-10, CPT, ACPCS, or MDC. This process also aligns provider and facility identifiers using entity resolution and reference databases to create unified profiles for accurate attribution. Cleansing focuses on correcting errors, filling in missing fields, removing duplicates, and harmonizing pair-specific formats, ensuring that only final and most relevant claim versions are retained. Both processes include compliance measures, such as de-identifying patient information while maintaining linkage keys for longitudinal analysis. Together, the normalization and cleansing work within the data factory transforms messy, inconsistent files into analytic-ready datasets that can be reliably linked, aggregated, and used to generate valid real-world evidence and answer some of the most complex clinical and commercial questions. We centralized this work within our data factory to enable agnostic and flexible productization, which provides Foreon with the advantage in offering a wide array of data-enabled offerings. While most of our clients contract for multi-year licenses, our Kronos Data Lake and Data Factory enable both ongoing and project-based offerings, such as health economics and outcomes research, supporting life science companies in demonstrating the value of new drugs and interventions. Through our acquisition of Kyber Data Science, we serve the financial services market with differentiated healthcare data expertise productized to meet the needs of institutional investors. Cyber offers a range of flexible solutions, from platform access for advanced data science teams to SaaS products that track the key utilization metrics across pharmacy and medical channels. Its team of healthcare data specialists deliver back-listed KPIs, AI-driven insights, and predictive analytics that enable more accurate investment decisions. We see opportunity to enhance these offerings by integrating Kyber with the foreign data factory and, over time, extending its advanced analytic capabilities into other tangential markets. We are optimistic about 2025. I can reconfirm outlook as we expect full year 2025 revenue of 28 to 30 million, representing 39 to 49% growth year over year. Our adjusted EBITDA margin is expected to be in the negative 1 to positive 1 million. Additionally, we remain committed to pursuing strategic value-enhancing acquisitions that strengthen our financial position, enhance our capital markets profile, expand our reach with pharmaceutical clients, and accelerate the commercialization of innovative products. I will now turn it over to Mike to run through the financials in detail.

Thanks, Max. Today I will provide an overview of Forian's financial results for the quarter ended June 30th, 2025. My discussion today will reference comparative results for the quarter ended June 30th, 2024, unless noted otherwise. As previously noted, we completed the acquisition of Kyber Data Science on October 31st, 2024. As a result, our operating results for 2025 include the operations of Kyber as of that date. The press release issued today presents Forian's financial results on a gap basis. As in prior quarters, we have also reported adjusted EBITDA, which management uses as a measure to track the performance of the business. As noted, the press release and these presentation materials include a detailed reconciliation of adjusted EBITDA to net income or loss. Our consolidated revenues of $7.5 million were up 2.7 million or 56% compared to the same quarter last year. The impact of the Kyber acquisition contributed approximately 1.9 million or 39% to the growth, with the remaining increase resulting from organic growth in our life sciences data business. Operating income was approximately $50,000 compared to a loss of 3 million in the same quarter last year. The increase in operating income was primarily due to the aforementioned higher revenues and lower stock-based compensation, partially offset by higher expenses related to the inclusion of Kyber operations and increased data costs. Net other income decreased 0.1 million from the prior year, from 0.4 million to 0.3 million, due to lower interest income and expense, resulting from the utilization of our cash and marketable securities balance to retire convertible notes in 2024. During 2024, we retired $17 million in principal value of our convertible notes, which we're doing September 2025 for a gain, resulting in a lower interest-bearing cash and marketable securities balance in the current year. Adjusted EBITDA. which excludes stock-based compensation, depreciation, amortization, costs related to litigation, and certain other non-recurring items was $0.6 million compared to $0.1 million in the same quarter last year. The increase in adjusted EBITDA resulted primarily from the higher revenues and incremental expenses related to the inclusion of Kiber and higher data costs noted above. As noted earlier, A reconciliation of our net income or loss to adjusted EBITDA along with an explanation of the reconciling items is included in today's earnings release. Now turning to our balance sheet, we ended the period with $35.6 million of cash and marketable securities and $6.8 million in convertible notes and accrued interest maturing in September 2025. After the planned maturity of remaining notes next month, we will continue to maintain adequate capital to operate our business and capitalize on incremental growth opportunities as they arise. Reviewing our financial outlook, we ended 2024 with revenues of $20.2 million and adjusted EBITDA of $0.5 million. Our outlook for 2025 is for revenue of $28 to $30 million reflecting growth of 39% to 49% over the previous year, and adjusted EBITDA between negative $1 million and positive $1 million. Now I will return the call over to the operator, who will open the line for questions.

Thank you. And as a reminder, to ask a question, simply press star 11 to get in the queue and wait for your name to be announced. To withdraw your question, simply press star 11 again. One moment. We have a question from the line of Richard Baldry with Roth Capital. Please proceed.

Thanks, and congrats on the good organic growth. Can you talk about what in the second half will really be the driver of the delta between whether you hit the top or the bottom line of the guidance that you've got? Is it you know, ramping existing contracts that you have some visibility into or newer wins, or is there some go-get on things that are in the pipeline and still have to close? Thanks.

Sure. Thank you, Richard. With the Kyber acquisition, the typical contract is an annual license versus the multi-year contract that we had previously with the life science part of the business. So we have a good portion of renewals that come in the back half of the year, and that has a large impact on hitting the guidance range. We feel confident, but we still have to hit those renewals.

Got it. Can you talk a little bit about the acquisition environment, what you're seeing out there in terms of pipeline you have to look at, realism on the sides of the sellers, valuations, just so we get an idea, because even after you pay down the converts, there's still a pretty significant cash balance left, right?

Yeah, happy to. We're seeing valuations come down from the highs that we had a year or so ago, especially the equity, high growth equity or venture-backed entities. A lot of companies that invested early in AI and have come back down to realization besides the ones that are really leading. So we are seeing opportunities in the smaller market that makes sense with our size company. From the public valuation perspective, it's a little bit of a mix. I would say a lot of the relatively small merger or acquisition candidates still trade at a premium to us. That might be a idiosyncratic to our specific volume economics of our stock. But we do see a larger willingness for companies to entertain different strategic conversations. So we are looking at both opportunities as active as we can to see something that's accretive. But it is... Sorry. It is... a top topic of management, and we constantly look for the right partners or targets to make the best use of our cash.

And last, maybe moving back to the organic growth side of the table, can you talk about where the strengths were there that drove that number, how sustainable or extensible you view that in the second half and longer term up to 26 and beyond? Thanks.

Sure. I mentioned it a couple of times, but our health economics outcomes research studies have really been a strong point for Forian. We have been able to repeatedly show that we are expert in putting together these services for the high value areas of life sciences and pharma in particular. So we see that pipeline as growing and a high win rate. and we expect that to be one of the primary growth indicators going into 2026. Outside of that, the kyber data science has been growing as we hoped it would into the financial service markets where complex questions for our hedge funds are really getting answered with really accurate models and offerings from that division. So those two areas are really leading our organic growth.

Maybe one more for me. Your second half guidance implies sort of stable, you know, top line. And you just posted, you know, a pretty good adjusted EBITDA number. So it's sort of similar to my revenue question to start. What would be the delta between, you know, a positive of a million versus a negative of Is it really sort of discretionary spend on strategic initiatives, or is it whether the revenue comes in at the upper or lower ends?

Yeah, it's both. Obviously, we have strong incremental margins, but from the bottom line, if we decide to invest in more data assets or to invest in tangential businesses that I believe can generate more revenue – the cost profile might hit the back half of this year where the revenue might be following. So that's really the largest impact on cost. Revenue is really tied to your previous question where if we can get the renewals as expected and hit our kind of historical go-get, we should be at the top end of the range.

Maybe always one last question. Can you talk about in your data engine, sort of the cost side internally to sort of do the work you're doing? Are you seeing, as we're hearing from other companies that are seeing a really good ability to use new leveraged AI technologies to get a lot more productivity from some other more expensive engineering headcounts? you know, sort of intermediate to long-term, how much do you think that can change sort of your COGS line or speed to develop new offerings, et cetera?

Thanks. Happy to. We're currently investigating that it is closer to our R&D line than our COGS. Our engineering using new AI agents or tools that will make them be more efficient is something that we believe all technology companies will need to embrace. I think the scrutiny of dealing with the large data that we deal with and the sensitivity around HIPAA and other areas that we really excel in has been a limiting factor in just adopting more experimental AI engines on the ingestion side. Though we do constantly look at it and do believe that we can get more output per employee using the right AI support. And then on the delivery and product side, we do see AI as being part of offerings going forward. Our first step of that is in the Kyber offering that is highly predictive using AI that could not be matched by normal machine learning. So we're very excited for that to be our first touch into it, but it's still a small percentage of our total offering.

Great. Thanks.

Thank you. And this concludes our Q&A session and program for today. Thank you all for participating. You may now disconnect.